Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $174
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Ann Hynes has maintained an Outperform rating on Quest Diagnostics and raised the price target from $160 to $174.
October 24, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho has maintained an Outperform rating on Quest Diagnostics and increased the price target from $160 to $174, indicating positive expectations for the stock.
The increase in price target from $160 to $174 by Mizuho suggests a positive outlook for Quest Diagnostics, likely leading to a short-term increase in stock price. The Outperform rating indicates confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100